Profile data is unavailable for this security.
About the company
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
- Revenue in USD (TTM)33.34m
- Net income in USD-17.55m
- Incorporated1976
- Employees179.00
- LocationEnzo Biochem Inc60 EXECUTIVE BLVDFARMINGDALE 11735United StatesUSA
- Phone+1 (516) 755-5500
- Websitehttps://www.enzo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 56.08m | 49.00 | -- | 1.25 | -- | 692.32 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 57.14m | 151.00 | -- | 0.6639 | -- | 1.10 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Mural Oncology PLC | 0.00 | -173.30m | 57.59m | 117.00 | -- | 0.2797 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Serina Therapeutics Inc | 179.00k | -18.67m | 58.80m | 4.00 | -- | -- | -- | 328.46 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Bioqual Inc | 62.86m | 957.02k | 60.37m | 108.00 | 63.08 | 1.55 | 17.21 | 0.9604 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Enzo Biochem Inc | 33.34m | -17.55m | 60.72m | 179.00 | -- | 0.8757 | -- | 1.82 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| VolitionRX Ltd | 976.52k | -32.42m | 60.79m | 110.00 | -- | -- | -- | 62.25 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Vor Biopharma Inc | 0.00 | -118.09m | 61.56m | 168.00 | -- | 0.6273 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Kronos Bio Inc | 8.41m | -102.85m | 62.10m | 58.00 | -- | 0.5041 | -- | 7.38 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Rapt Therapeutics Inc | 0.00 | -120.43m | 62.48m | 122.00 | -- | 0.572 | -- | -- | -3.12 | -3.12 | 0.00 | 3.13 | 0.00 | -- | -- | 0.00 | -69.23 | -46.30 | -75.81 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.51m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -20.60m | 63.32m | 31.00 | -- | 1.65 | -- | -- | -1.43 | -1.43 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -56.37 | -58.43 | -59.43 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 64.84m | 210.00 | -- | -- | -- | 1.26 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
| Celularity Inc | 22.77m | -196.30m | 65.51m | 120.00 | -- | 1.41 | -- | 2.88 | -11.29 | -11.29 | 1.30 | 2.11 | 0.0836 | 2.90 | 2.39 | 189,758.30 | -72.04 | -19.19 | -94.47 | -20.99 | 29.66 | -- | -862.04 | -454.79 | 0.2086 | 1.37 | 0.4893 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
Data as of Sep 21 2024. Currency figures normalised to Enzo Biochem Inc's reporting currency: US Dollar USD
22.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harbert Fund Advisors, Inc.as of 30 Jun 2024 | 5.18m | 10.06% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 2.50m | 4.86% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.86m | 3.62% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 887.99k | 1.73% |
| Geode Capital Management LLCas of 30 Jun 2024 | 356.90k | 0.69% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 294.03k | 0.57% |
| RBF Capital LLCas of 30 Jun 2024 | 250.36k | 0.49% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 154.14k | 0.30% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 132.10k | 0.26% |
| Wittenberg Investment Management, Inc.as of 30 Jun 2024 | 117.14k | 0.23% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
